Is This Leading COVID Stock a Buy Right Now?
Pfizer (NYSE: PFE), the developer of the top-selling COVID-19 vaccine in the world known as Comirnaty alongside its German partner BioNTech (NASDAQ: BNTX), has performed very well this year. In fact, Pfizer's stock is up 47% so far this year, which is significantly higher than the S&P 500's 24% appreciation year to date.
This raises the following question: Is Pfizer's stock still a buy or has the stock gone up too far, too fast?
Image source: Getty Images.
Source Fool.com
